The global endoscopic submucosal dissection market is projected to generate USD 512.9 million revenue by 2030, advancing at a CAGR of 5.5% during 2022–2030. The key factors driving the market are the rising incidence of targeted diseases, increasing use of endoscopies in treatment, and growing geriatric population.
Endoscopic submucosal dissection is done for lesions more than 3 cm in size. The procedure was initially developed in Japan for the en-bloc resection of gastric tumors in the early stage, and now, it has become a key interventional approach in Western countries. It is also being increasingly employed for the resection of colorectal lesions. An ESD allows for the sophisticated and anatomically reliable resection of flat lesions 2 cm in size or larger and laterally spreading polyps.
Tissue retractors held a share of around 30% in 2022, as they are ideal for incisions of various sizes and shapes. This instrument is useful in many surgeries to protect the wound from further damage and infection, is atraumatic, the minimal exposure is afforded, and the incision is minute. Additionally, this device protects intercostal nerves because it does not stretch the intercostal muscles or intercostal space with too much force. Additionally, the flexibility and strength of the instrument allow surgeons to visualize wound margins, retain moisture at the incision site, and significantly reduce wound infection risk.
The growth of the North American market can be ascribed to the rising frequency of technological advancements, surging geriatric population, increasing prevalence of chronic diseases, especially gastric disorders; presence of giant players, improving healthcare services, and increasing number of hospitals.
Additionally, the demand for endoscopies is increasing among the elderly population as it is more prone to chronic diseases, such as cancers, blockages, and gastroesophageal reflux disease (GERD). These diseases require GI endoscopies and colonoscopies for diagnosis, thus leading to an increase in the usage of endoscopes in the region. Moreover, the U.S. is undergoing a demographic shift with the surge in the number of people aged 65 years and older. This age group’s share in the total population is projected to rise to around 25% (more than 95 million) by 2060 from around 15% (more than 50 million) in 2018.
Furthermore, the surge in the capital expenditure on the healthcare infrastructure and the growing number of hospitals and imaging centers in North America, as a result, are driving this market. In the U.S., in the annual survey, the American Hospital Association has estimated the total number of hospitals associated with itself at more than 6,000. Apart from disease diagnosis and management, endoscopy plays an important role in clinical research as well; numerous hospitals in the region have a dedicated research department.
Similarly, in the LATAM region, the endoscope submucosal dissection market value is rising at a fast pace with advancements in technology. The occurrence of numerous GI disorders is significant in the region, which is boosting the number of endoscopies. In 2020, stomach and colon cancers were the fifth- and third-most-common cancers, and the occurrence of inflammatory bowel syndrome (IBS) in the region is surging too.
Major players operating in the endoscopic submucosal dissection market include Olympus Corporation, Boston Scientific Corporation, FUJIFILM Holdings Corporation, Sumitomo Bakelite Co. Ltd., Creo Medical Plc, MTW-Endoskopie W.Haag KG, Ovesco Endoscopy AG, KARL STORZ SE & Co. KG, CONMED Corporation, and Micro-Tech Endoscopy.